<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037994</url>
  </required_header>
  <id_info>
    <org_study_id>6909</org_study_id>
    <nct_id>NCT05037994</nct_id>
  </id_info>
  <brief_title>Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Frozen Shoulder</brief_title>
  <official_title>Ultrasound Guided Continuous Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Patients With Frozen Shoulder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients will be randomly allocated into two equal groups (each 20 patients) using sealed&#xD;
      opaque numbered envelopes:&#xD;
&#xD;
      Control Group (C Group) : Patients receive continuous US suprascapular nerve block only.&#xD;
&#xD;
      Gabapentin Group (G Group) : Patients receive continuous US suprascapular nerve block with&#xD;
      oral gabapentin 300 mg once daily at bed time.&#xD;
&#xD;
      Both groups compared as regard:&#xD;
&#xD;
      Visual Analogue Scale Range of passive and active movements Patients satisfaction&#xD;
      complication related to block The total dose of diclofenac sodium&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Actual">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>10cm line where zero means no pain and ten means worse imaginary pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of passive and active movements</measure>
    <time_frame>6 weeks</time_frame>
    <description>by goniometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients satisfaction</measure>
    <time_frame>6 weeks</time_frame>
    <description>by questionnaire with 3 degrees&#xD;
Fair&#xD;
Good&#xD;
Excellent</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The total dose of diclofenac sodium</measure>
    <time_frame>6 weeks</time_frame>
    <description>Indicator for analgesia required</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pain, Shoulder</condition>
  <arm_group>
    <arm_group_label>Control Group (C Group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive continuous US suprascapular nerve block only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin Group (G Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine</intervention_name>
    <description>The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.&#xD;
Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap.</description>
    <arm_group_label>Control Group (C Group)</arm_group_label>
    <arm_group_label>Gabapentin Group (G Group)</arm_group_label>
    <other_name>Oral gabapentin 300 mg at bed time in GG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index ≥ 18 Kg/m2 ≤ 30Kg/m2&#xD;
&#xD;
          -  ASA I, II or III.&#xD;
&#xD;
          -  Cooperative patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  local infection at site of injection.&#xD;
&#xD;
          -  coagulopathy&#xD;
&#xD;
          -  previous history of mental disorders or chronic drug abuse (opioids, tranquilizers)&#xD;
&#xD;
          -  known hypersensitivity to any of the drugs used in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMAD S HEGAB, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant professor of Anesthesia &amp; Surgical Intensive Care Faculty of Medicine - Zagazig University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amr Shaaban Elshafei</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Amr Shaaban Elshafei</investigator_full_name>
    <investigator_title>AMR SHAABAN ELSHAFEI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bursitis</mesh_term>
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

